Both companies will use their platforms to accelerate drug discovery and development
News
Alladapt’s allergy treatment receives FDA fast track designation
ADP101 is an oral immunotherapy to treat multi-food and single-food allergies
PREDICTOM trial backed by €21m for early Alzheimer’s detection
The trial will use an AI screening platform to identify those most at risk of dementia
Thousands of men to participate in UK trial for prostate cancer
Prostate cancer is responsible for 12,000 deaths every year in the UK
Two charities co-fund £5.5m childhood cancer research programme
SMPaeds2 aims to advance precision medicines for children with relapsed cancer
Lab-grown blood vessels could potentially treat strokes and vascular dementia
Cerebral SVD contributes to 45% of dementia cases and 20% of ischaemic strokes
NHS expands COVID-19 research platform for other major diseases
The OpenSAFELY platform will support the discovery of new treatments
BHF and UKDRI announce first UK centre for vascular dementia research
The centre will help discover new treatments to prevent, halt and cure the condition
New NIHR Research Delivery Network in England announced by DHSC
The University of Leeds and NHS organisations will host the network in 2024
NHS trials artificial intelligence system to prevent avoidable admissions
The AI system will identify those most at risk and reduce pressure on the NHS
LifeArc and UKDRI invest £14.5m into neurodegeneration research
The funding will be used to develop new diagnostic tests, treatments and devices
Glox Therapeutics secures £4.3m seed funding to combat AMR
The bacteriocin development programme will first target pseudomonas aeruginosa
JCVI advises UK government on gonorrhoea and mpox vaccinations
Both programmes will be offered to those most at risk of developing STIs
Study shows how congenital heart disease affects blood supply before birth
CHD is a common birth defect that affects the development of the heart and brain
Documentary highlights new targets to potentially treat motor neurone disease
The terminal condition currently affects around 5,000 people in the UK
